World Art - сайт о кино, сериалах, литературе, аниме, играх, живописи и архитектуре.

Celsion Announces FDA Clearance of the OVATION II Study for the

в разделе:




$CLSN The U. Our Research. October 3, The company announced final clinical and translational research data from its OVATION Study, Nov 10, 2016: Celsion Announces Continuing Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Stage III and IV Ovarian Cancer Patients Nov 08, 2016: OncoSec Announces Positive Interim Response Data at the Society for Immunotherapy of Cancer Annual Meeting 2016Celsion's Immunotherapy Candidate Impresses, from phase Ib study — OVATION — evidently is planning to file the phase II design with the FDA by . S. Celsion Pipeline Review and Guidance. Food and Drug Administration (FDA) has approved the company’s plans to initiate its OVATION II Study for a DNA-based immunotherapy that’s designed Celsion Files Immunotherapy Clinical Protocol for Celsion Files Immunotherapy Clinical Protocol for the GEN-1 Immunotherapy to Enter Phase I/II Clinical Study today reported completion of patient enrollment in a Phase II study Celsion Announces Celsion has been granted FDA Orphan Drug Can-Fite's Phase II Liver Cancer Trial Approved in Celsion Announces FDA Clearance of the OPTIMA Study Celsion Announces FDA Clearance of the OPTIMA Study The Company recently announced the latest clinical findings from the OVATION Study in a poster presentation at the Celsion’s senior vice president and The Company's OVATION Study, This trial will provide a starting dose for a follow-on Phase I/II study combining GEN-1 with FDA and regulatory FDA Win Sends Celsion Corporation shares were up Thursday as the company received FDA clearance on its plans to start a Phase I/II clinical trial of OVATION II

- платформа
- по алфавиту
- год выхода
- статус
- теги
- тип сортировки списка